Cargando…
Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting
BACKGROUND: Genetics-based basket trials have emerged to test targeted therapeutics across multiple cancer types. However, while vemurafenib is FDA-approved for BRAF-V600E melanomas, the non-melanoma basket trial was unsuccessful, suggesting mutation status is insufficient to predict response. We hy...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822426/ https://www.ncbi.nlm.nih.gov/pubmed/31672130 http://dx.doi.org/10.1186/s12885-019-6175-2 |